Department of Obstetrics and Gynaecology, College of Medicine and Health Sciences, Afe Babalola University/Federal Teaching Hospital, Ido-Ekiti, Nigeria.
Institute of Maternal and Child Health, Lagos State University Teaching Hospital, Lagos, Nigeria.
J Matern Fetal Neonatal Med. 2022 Dec;35(25):7695-7700. doi: 10.1080/14767058.2021.1960969. Epub 2021 Aug 17.
Pre-eclampsia is a major cause of maternal and fetal morbidity and mortality in both developed and developing countries. Hyperuricemia is often associated with pre-eclampsia and when this occurs, fetal outcome may become worse. We evaluated the role of maternal serum uric acid as a prognostic indicator of fetal outcome in pre-eclamptic mothers.
A prospective case-control study in which 55 eligible pre-eclamptic patients at term were matched in maternal age and gestational age with 55 consecutive normotensive pregnant women. Venous blood samples were obtained and analyzed for serum uric acid. Following delivery, the fetal outcomes in the pre-eclamptic group and controls were determined. Data analysis was carried out using SPSS (version 21) and the level of statistical significance was set at -value <.05.
The mean serum uric acid levels of the pre-eclamptic subjects was significantly higher compared to their normotensive counterparts (12.7 ± 7.8 vs. 4.9 ± 1.2 mg/dL, = .000). Babies with low birth weight, poor Apgar scores (at 1st and 5th minute of life) and those who required neonatal unit admission occurred more significantly among the pre-eclamptic women when compared with the controls ( = .000). However, the live birth rate of the case and control groups was comparable (94.5% vs. 100%, = .079), Binary logistic regression analysis revealed a positive association between hyperuricemia and pre-eclampsia (OR = 18.8; 95% CI = 1.22-289.35, = .035). Pre-eclamptic mothers with hyperuricemia had 4.41 odds of delivering babies with low birth weight when compared with pre-eclamptics without hyperuricemia (OR = 4.41; 95% CI = 0.76-25.5, = .097); but Apgar scores and need for neonatal admission showed no association with maternal serum uric acid levels.
This study therefore suggests that hyperuricemia is a strong prognostic indicator of LBW babies among women with pre-eclampsia.
子痫前期是发达国家和发展中国家孕产妇和胎儿发病率和死亡率的主要原因。高尿酸血症常与子痫前期相关,当这种情况发生时,胎儿结局可能会恶化。我们评估了母体血清尿酸作为子痫前期母亲胎儿结局的预后指标的作用。
这是一项前瞻性病例对照研究,其中 55 名符合条件的足月子痫前期患者按母亲年龄和孕龄与 55 名连续正常妊娠孕妇相匹配。采集静脉血样并分析血清尿酸。在分娩后确定子痫前期组和对照组的胎儿结局。数据分析使用 SPSS(版本 21)进行,统计显著性水平设置为 - 值<.05。
与正常血压孕妇相比,子痫前期患者的平均血清尿酸水平明显升高(12.7±7.8 与 4.9±1.2mg/dL, = .000)。与对照组相比,子痫前期妇女中低出生体重、低 Apgar 评分(出生后 1 分钟和 5 分钟)和需要新生儿重症监护室入院的婴儿更为显著( = .000)。然而,病例组和对照组的活产率相当(94.5%与 100%, = .079)。二元逻辑回归分析显示高尿酸血症与子痫前期之间存在正相关(OR=18.8;95%CI=1.22-289.35, = .035)。与无高尿酸血症的子痫前期患者相比,高尿酸血症的子痫前期母亲分娩低出生体重婴儿的几率为 4.41 倍(OR=4.41;95%CI=0.76-25.5, = .097);但 Apgar 评分和新生儿入院需求与母体血清尿酸水平无关联。
因此,本研究表明,高尿酸血症是子痫前期妇女中低体重婴儿的一个强有力的预后指标。